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1. Introduction 
Chronic kidney disease (CKD) is a syndrome characterized by the progressive and 
irrevocable loss of nephrons due to several diseases. Chronic kidney disease has a varying 
spectrum ranging from normal renal function to uremic syndrome. Actually, the stages of 
renal failure have interpenetrated each other and it is not possible to draw a clear line 
between them. The most important reason of mortality and morbidity of patients with CKD 
are cardiovascular diseases and atherosclerotic complications; cardiac insufficiency 15%, 
myocardial infarction 10%, pericarditis 3% (1, 2). Development of vascular injury in CKD is 
caused by both classic (Framingham) risk factors (hypertension, dyslipidemia, smoking, 
diabetes mellitus) and CKD specific factors (anaemia, secondary hyperparathyroidism etc). 
Besides, there are papers reporting that recently defined potential risk factors such as 
homocysteine (Hcy), C-reactive protein (CRP), interleukin-6 (IL-6), fibrinogen, soluble 
intracellular adhesion molecule (sICAM-1), asymmetric dimethyl arginine (ADMA), cardiac 
specific troponin-I (cTnI), advanced glycation endproducts have a role in the development 
of accelerated atherosclerosis seen in patients with CKD (2-13). Asymmetric 
dimethylarginine (ADMA) is an endogenous competitive inhibitor of nitric oxide (NO) 
synthase and it is a guanidine analogue of L-arginine aminoacid detectable in human urine 
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and plasma synthesized from endothelial cells (Figure 1). It is shown that high ADMA level 
increases the cardiovascular incident risk by 34% and mortality risk by 52% (4-8). Increased 
ADMA concentration has a high prevalence in hyperhomocysteinemia, coronary artery 
diseases, hypercholesterolemia, diabetes mellitus, hypertension, preeclampsia, peripheral 
arterial occlusive disease, impaired renal function and other diseases (7,9,10). Reduced nitric 
oxide (NO)-dependent vasodilation is regarded as an early indicator of atherosclerotic 
diseases (7,14). It is documented that adult patients with renal failure have 2-6 times higher 
ADMA than healthy subjects due to reduced renal excretion and reduced enzymatic 
degradation (15). NO is synthesized from L-arginine via NO synthase enzyme. NO 
inhibition decreases endothelial derived vasodilation and increases vascular resistance. 
Reduced NO availability can occur in patients with CKD. Moreover CKD can contribute to 
the accelaration of hypertension and cardiovascular complications. It appears that the 
increase in endogenic NO inhibitors like ADMA plays a major role in this process (11, 15-
17). It has been shown that Hcy stimulates ADMA formation and plasma ADMA levels 
elevate in humans and animals by hyperhomocysteinemia (18-20). Increased serum Hcy 
level in adult CKD patients is an independent risk factor for cardiovascular system 
mortality. Elevated ADMA and hyperhomocysteinemia may be due to decreased renal 
excretion (18-22). It is reported that ADMA formation may be related with Hcy metabolism 
(18,19). It was found that there is a significant interaction of serum fibrinogen and CKD with 
respect to risk of both fatal/nonfatal coronary events and death (20–24).  
 
Fig. 1. Biochemical pathway for generation and degradation of ADMA and homocysteine. 
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The aim of this study was to investigate the role of uremia-related cardiovascular risk 
factors, such as ADMA, NO, Hcy and fibrinogen, in the pathogenesis and progression of 
early stage CKD and to evaluate the relation of these parameters with each other.  
2. Material and methods 
2.1 Subjects  
This prospective study was carried out in 65 untreated mild chronic kidney disease (35 
men and 30 women; mean age 55.2 ± 9.6 years) and 65 healthy control subjects with 
matched age, sex and body mass index (BMI). The creatinine clearance was calculated by 
the Cockcroft-Gault Formula (25). Patients having creatinine clearance less than 75 ml/min 
were considered to have mild CKD. Body mass index was determined as weight divided 
by the square of height (kg/m2). The underlying causes of CKD were glomerulonephritis 
(n=17), interstitial nephropathy (n=12), autosomal dominant polycystic kidney disease 
(n=13), chronic pyelonephritis (n=7) and urological problems (n=5). No cause was 
identified in 11 cases. The exclusion criteria were diabetes mellitus, active hepatitis, 
malignancy, smoking and infectious disease. Patients using vitamin supplements were also 
excluded. 
The study protocol was approved by the Ethics Committee of the Dicle University School of 
Medicine (Diyarbakir, Turkey) and written informed consent was obtained from each 
participant. 
2.2 Methods 
In all patients, venous blood samples were drawn between 7:00 AM after a 12-h fastened, 
and the serum was frozen at -70˚ C in aliquots until biochemical analysis were performed.  
ADMA Measurement: ADMA was measured by HPLC according to the method described by 
Chen et al. (26). Mobile phases consisting of 50 mM sodium acetate (pH 6.8), methanol and 
tetrahydrofuran (THF) (A, 82:17:1; B, 22:77:1)  were used. All separations were performed at 
270C and at a flow-rate of 1.0 ml/min. The wavelengths of fluorescence detector were set at 
338 nm and 425 nm for excitation and emission, respectively. 20 mg of 5-sulfosalicylic acid 
(5-SSA) was added to 1 ml plasma, and the mixture was left in an ice bath for 10 min. The 
precipitated protein was removed by centrifugation at 2000 g for 10 min. o-
Phthaldialdehyde (OPA) (10 mg) was dissolved in 0.5 ml of methanol, and 2 ml of 0.4 M 
borate buffer (0.4 M boric acid adjusted to pH 10.0 with potassium hydroxide) and 30 μl of 
mercaptoethanol were added. The derivatization was performed by mixing 10 μl of sample 
or working standard solution and 100 μl of OPA reagent and reacting for 3 min before 
autoinjecting onto the column.  
NO Measurement: The serum level of NO was measured using a colorimetric method based 
on the Griess reaction (27), in which nitrite is reacted with sulphanilamide and N-(1-
naphthyl) ethylenediamine to produce an azo dye that can be detected at 540 nm. This was 
carried out after enzymatic reduction of nitrate to nitrite with nitrate reductase.  
Hcy Measurement: Serum level of Hcy was measured using HPLC with fluorescence 
detection (Shimadzu RF-10A fluorescence detector; Shimadzu Co., Kyoto, Japan).  
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Urea, creatinine, calcium, phosphate, albumin, protein, high sensitive CRP (hsCRP), insulin, 
glucose, total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density 
lipoprotein cholesterol (LDL-C) and triglyceride assays were determined by standard 
laboratory methods according to the established methodology.  The serum level of 
fibrinogen was measured by the Clauss method using a commercial kit. All routine 
laboratory measurements were carried out using certified assay methods.  
Statistical analysis of the differences between groups of subjects was performed using the 
Kolmogorov-Smirnov and unpaired student’s t-test or by the Mann-Whitney non-
parametric test as appropriate. Pearson’s correlation analyses were performed. 
3. Results 
Serum levels of ADMA, Hcy, creatinine, LDL-C and hsCRP were significantly (p<0.001) 
higher in patients with mild CKD than in healthy controls. Also, systolic and diastolic blood 
pressures were increased (p<0.001). There were no significant differences in levels of serum 
fasting blood glucose, insulin, total cholesterol, HDL-C, triglyceride, calcium and phosphate 
between the mild CKD and healthy controls (P>0.05). Serum NO and creatinine clearance 
levels were decreased in patients with mild CKD than in healthy controls (p<0.001). Clinical 
and laboratory data are reported in Table 1. In multiple linear regression analysis, ADMA 
level was negatively correlated with NO (r = -0.861; p<0.001) as shown in Figure 2A, and 
positively correlated with Hcy (r = 0.547; p<0.001, Figure 2B) and fibrinogen (r = 0.704; 
p<0.01, Figure 2C). ADMA level was positively correlated with creatinine (r=0.510;p<0.001), 
LDL-C (r=0.420;p<0.01), hsCRP (r=0.525;p<0.001), systolic (r=0.375; p<0.001) and diastolic 
blood pressure (r=0.410;p<0.001) levels. ADMA level was negatively correlated with GFR 
(r=-0.720;p<0.001). Also, serum NO level was negatively correlated with homocystein (r = -
0.390; p<0.001, Figure 3). We found no association between ADMA and HDL-C or other 
parameters in either subjects with mild CKD.  
4. Discussion 
The findings of the present study are as follows: (1) Serum ADMA level is increased in 
patients with CKD compared with healthy subjects and is associated with decreased NO 
and GFR. (2) Elevation of circulating serum ADMA is associated with increased Hcy and 
fibrinogen in CKD patients. (3) Serum NO level as dependent variable was also negatively 
correlated with Hcy. Our findings suggested that the ADMA levels can reflect a possible 
independent role in CKD pathogenesis. Increased ADMA serum levels cause persistent 
renal vasoconstriction and sodium retention, and contributes to the development of high 
blood pressure (11). In addition, it might influence NO and GFR levels and affect 
atherosclerosis formation. 
Several studies suggested that ADMA level can be an independent risk factor for 
progression of CKD (3-13). Elevated ADMA reduces bioavailability of NO and induces 
endothelial dysfunction and may be involved in the pathophysiology of cardiovascular 
disease in CKD (8). ADMA fulfils many of the characteristic features of an uremic toxin 
(14,15). Elevation of circulated ADMA, an endogenous inhibitor of nitric oxide synthase, is 
an independent risk factor for cardiovascular diseases in predialysis patients with CKD 
(5,14,15). High ADMA levels lead to NO depletion, impaired endothelium-dependent  
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 Healthy Subjects 
(n=65) 
Chronic Kidney Disease 
(n=65) 
Age (years) 54.9 ± 10.1 55.2 ± 9.6 
Number of patients (M/F) 35/30 35/30 
Body mass index (kg/m2) 24.90 ± 2.1 24.70 ± 2.6 
Systolic BP (mmHg) 110.20 ± 10.4 *128.40 ± 22.4 
Diastolic BP (mmHg) 72.20 ± 11.6 *84.40 ± 16.3 
Creatinine clearance (ml/min) 90.20 ± 15.1 *52.50 ± 15.3 
Urea (mg/dl) 31.50 ± 6.2 *61.30 ± 14.6 
Creatinine (mg/dl) 1.20 ± 0.42 *1.61 ± 0.73 
Calcium (mg/dl) 8.73 ± 1.2 8.91 ±1.08 
Phosphate (mg/dl) 4.10 ± 1.09 4.09 ± 1.2 
Albumin (g/dl) 3.82 ± 0.9 3.94 ± 0.5 
Protein (g/dl) 6.40 ± 1.1 6.01 ± 0.3 
Glucose (mg/dl) 87.90 ± 16.2 90.10 ± 15.4 
Insulin (µu/ml) 11.60 ± 2.9 12.04 ± 2.83 
Triglyceride(mg/dl) 118.30 ± 20.2 120.10 ± 18.5 
Total cholesterol (mg/dl) 184.20 ± 22.1 185.60 ± 19.4 
HDL-C (mg/dl) 45.80 ± 12.4 42.02 ±14.3 
LDL-C (mg/dl) 113.20 ± 12.8 *142.12 ± 18.6 
hsCRP (mg/dl) 1.914 ± 0.667 *7.048 ±2.249 
Fibrinogen (g/L) 2.835 ± 0.646 *4.574±0.521 
ADMA (µmol/L) 0.512  ±  0.116 *0.837±0.189 
Nitric oxide (µmol/L) 75.67  ±  8.626 *44.31±7.811 
Homocystein (µmol/L) 6.256 ± 1.629 *18.37 ± 3.192 
*P < 0.001; Data are reported as means ± SD. 
BP: Blood Pressure; HDL-C: High Density Lipoprotein Cholesterol; LDL-C: Low Density Lipoprotein 
Cholesterol; hsCRP: High sensitive C Reactive Protein; ADMA: Asymmetric dimethylarginine 
Table 1. Clinical and laboratory data of patients with CKD and healthy subjects. 
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Fig. 2. Correlation between asymmetric dimethylarginine (ADMA) and (A) nitric oxide 
(NO), (B) homocysteine (Hcy), and (C) fibrinogen. 
 
Fig. 3. Correlation between nitric oxide (NO) and homocysteine (Hcy). 
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vasodilation and plaque rupture with thrombus formation (8). In addition, increased ADMA 
level in circulation is a combined result of decreased elimination and reduced activity of 
ADMA catabolism by dimethylarginine dimethylaminohydrolase (DDAH) (8,9). Elevated 
plasma levels of ADMA in patients with end stage renal disease (ESRD) were first reported 
by Vallance et al. (15). Several recent studies have already indicated that elevated plasma 
ADMA levels could cause cardiovascular morbidity and mortality in progressive chronic 
kidney disease (4-13). Mihout et al. (9) demonstrated that high plasma ADMA levels 
contribute to the development of hypertension, oxidative stress, and interstitial and 
glomerular fibrosis, and peritubular capillary rarefaction. This may be involved in the 
decline of renal function. Serum levels of ADMA in CKD are predictive of renal survival 
and of cardiovascular damage. High ADMA levels are associated with endothelial 
dysfunction and oxidative stres (12). In the study by Young et al. (8) , there was a strong 
association of ADMA with prevalent cardiovascular disease and a modest association with 
all-cause and cardiovascular disease mortality. ADMA is strongly associated with intima-
media thickness of the carotid artery and left ventricular mass, particularly concentric left 
ventricular hypertrophy (11). 
Coen et al. (12) suggested that ADMA levels could be influenced by the severity of 
hyperparathyroidsm and contribute to cardivascular death linked to parathyroid hormone 
(PTH) of hemodialysis patients. Another study conducted by Shi et al (5) has shown that the 
circulating level of ADMA is an important risk factor of LVH and predicts CVD in pre-
dialysis CKD patients. 
Selcoki et al. (10) reported that ADMA level was to be one of the strongest risk markers for 
atherosclerosis in patients with mild and moderate CKD. Ninety percent of ADMA has been 
metabolized by DDAH, while the other small portion, 10 %, is excreted by urinary system. 
Potential mechanisms of elevated plasma ADMA levels in renal failure are increased protein 
methylation, increased proteolysis, impaired renal excretion and impaired metabolism by 
DDAH (18). These results are consistent with data from our study. Our results suggest that 
high ADMA level can be a significant risk factor for progression of renal dysfunction in the 
earlier stages of CKD.  
Several recent studies found markedly elevated plasma ADMA levels not only in patients 
with ESRD, but also in patients with progressive CKD (2). It is of note that our results are in 
line with a recent study by Nakamura et al. (28), who found that elevation of serum ADMA 
levels play a role in the progression of atherosclerosis and CKD in high-risk patients. 
Studies in both the general population and the dialysis population showed a strong and 
independent link between ADMA, all-cause mortality, and cardiovascular events 
(11,12,21,24). As a consequence, elevated serum levels of ADMA may be of relevance not 
only in vascular pathology but also in the pathophysiology of hypertension, and in paralel, 
in the development of renal damage (13). 
When ADMA accumulates in CKD due to defective inactivation and excretion, it is a factor 
of impaired NO synthesis. The decrease in the generation of NO lead to endothelial 
malfunction and damage (12). Nitric oxide is an important molecule which has many 
physiological functions, such as mediating vasodilation, inhibiting atherosclerosis, and 
modulating the growth of the myocardium (5). Nitric oxide is produced from its precursor 
L-arginine via a reaction catalyzed by endothelial NO synthase (NOS) (8,9). Endothelium- 
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derived nitric oxide is a potent endothelial vasodilator which balances constrictors to 
regulate blood pressure and vascular tone (9). Leone et al. (35) suggested that NO may play 
a role in blood pressure regulation. NO is a cardiovascular protective substance because it 
causes vasodilation and leucocyte aggregation (10). Nitric oxide also plays a role in 
regulating renal sodium excretion and renin release (30). Nitric oxide, synthesised from L-
arginine, contributes to the regulation of blood pressure and to host defence (29). As an 
endogenous vasodilator it contributes to renal arteriolar tone and modulates relaxation of 
the mesangium, thus contributing to regulation of glomerular microcirculation. It has 
antiplatelet and antithrombogenic effects and thus helps prevent thrombosis within the 
glomerular capillaries (30). 
Clinical and experimental evidence suggest that the elevation of ADMA may cause a low 
production of NO (11,14-17,29,30). Synthesis of NO can be blocked by inhibition of nitric 
oxide synthase (NOS) activities with guanidino-substituted analogues of L-arginine such as 
ADMA (28). Accumulation of endogenous ADMA, leading to impaired NO synthesis, might 
contribute to the hypertension and immune dysfunction associated with chronic renal 
failure (29). Reduced bioavailability of NO, increased systemic blood pressure, endothelial 
cell injury and dysfunction are thought to play an important role in progressive kidney 
damage (7). Endothelial dysfunction due to reduced availability of NO is an early step in the 
course of atherosclerotic vascular disease (7). Increased ADMA blood levels may contribute 
to this process. In addition, NO inhibits key processes of atherosclerosis, such as monocyte 
endothelial adhesion, platelet aggregation, and vascular smooth muscle cell poliferation 
(31).  
In our study, while serum ADMA and Hcy levels were significantly higher in the patients 
with CKD than in healthy subject, the NO level was significantly lower. Our findings 
were in agreement with previous studies (7,9,10,18). Low NO is a major feature of chronic 
kidney diseases. We examined the relationship of ADMA with NO and with Hcy in CKD 
patients. In this prospective study, high ADMA level was associated with both decreased 
NO and increased Hcy. Similarly, Strong relationships between increased serum Hcy, 
fibrinogen, ADMA and decreased NO, GFR and mortality from cardiovascular events 
have recently been demonstrated. Several prospective clinical studies have shown that 
ADMA, fibrinogen, Hcy, LDL-C and other cardiovascular risk parameters are effected in 
patients with CKD, atherosclerosis, hypertension, diabetes and other clinical entities (14-
18,22). 
The major factor for high plasma ADMA levels in renal failure seems to be a decrease 
DDAH activity, which in turn may be due to increased oxidative stress and/or 
hyperhomocysteinemia (18). Recent studies show contradictory data regarding the role of 
hyperhomocysteinemia on cardiovascular morbidity and mortality in CKD patients (32). 
Rasmussen et al. (22) suggested that elevated homocysteine level is an independent 
predictor of cardiovascular events in patients with ESRD. Ninomiya et al. (33)  suggested 
that baseline Hcy level showed a significantly inverse association with rate of change in 
kidney function during the 5 years after being adjusted for confounding factors, including 
baseline kidney function.  
One study indicates a linkage between hyperhomocysteinemia, oxidative stress and ADMA 
metabolism (32). Recently, it was hypothesized that some of the deleterious effects of 
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hyperhomocysteinemia may involve ADMA-related cardiovascular effect in CKD (18-20). 
Hyperhomocysteinemia, elevated plasma ADMA concentrations have first been described 
in patients with renal failure (18). Plasma levels of homocysteine and ADMA are elevated in 
patients with renal failure and both have been associated with cardiovascular events, 
possibly due to their negative effects on endothelial function. ADMA in methylation of 
homocystein plays an important role. Elevated homocysteine level is strongly related to 
renal function and probably due to decreased metabolic clearance (18-20). Homocysteine 
and ADMA are aminoacids which are biochemically linked by a common synthetic 
pathway. Homocysteine inhibits DDAH, the enzyme responsible for the breakdown of 
ADMA. Homocysteine may enhance protein degradation by destabilizing protein structure 
or by increasing oxidative stress, resulting in ADMA release (18).  
Contraversely, Simic-Ogrizovic et al. (24) suggested that although total serum Hcy level was 
not found to be a predictor of overall and cardiovascular mortality, the role of 
hyperhomocysteinemia as risk factor for cardiovascular disease cannot be excluded in 
hemodialysis patients.   
We found a strong association between ADMA levels and hyperfibrinogenemia, and 
hyperhomocysteinemia in our study. In addition, as inflammation index, CRP and 
fibrinogen were increased. Our results show that increased ADMA, Hcy, hsCRP and 
fibrinogen levels contribute to the progression of renal disease. Serum levels of ADMA and 
Hcy may interact and modulate the effect of each other, thus contributing to a common 
mechanism leading to cardiovascular diseases in CKD. These findings are similar to 
observations from previous studies (18-21). 
The level of serum fibrinogen (an inflammation marker) is increased in CKD. Increased 
serum fibrinogen level independently predicts cardiac events (20). Shishehbor et al. (19) 
suggested that Hcy and fibrinogen levels can explain nearly 40% of the attributable 
mortality risk from CKD. Bostom et al. (21) suggested that Hcy, lipoprotein(a) (Lp(a)), and 
fibrinogen interact to promote atherothrombosis, combined hyperhomocysteinemia, 
hyperfibrinogenemia, and, Lp(a) excess may contribute to the high incidence of vascular 
disease sequelae experienced by dialysis patients, which is inadequately explained by 
traditional cardiovascular disease risk factors. In our present study, the serum level of LDL-
C was significantly higher in the patients with CKD than in the healthy subjects. In addition, 
the ADMA level was positively correlated with LDL-C. The association of increased LDL-C 
with increased risk of coronary heart disease may be thought as a covariable in the oxidative 
activation of ADMA synthesis.  
Descamps-Latscha et al. (23) thought that CRP, fibrinogen and advanced oxidation protein 
products (AOPP) levels independently predict atherosclerotic cardiovascular events in 
patients with CKD in the predialysis phase and might directly contribute to the uremia-
associated accelerated atherogenesis. These findings lend support to the hypothesis that 
accumulation of ADMA is an important risk factor for cardiovascular events in CKD (2).  
Our findings suggest that high ADMA, fibrinogen and Hcy levels and NO deficiency may 
contribute to the process of atherosclerotic cardiovascular disease and other consequeces of 
uremia in predialysis patients with CKD. In addition, the ADMA level was associated with 
hyperhomocysteineamia and hyperfibrinogenemia. 
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